Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 6,437 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Clear all
Completed No phase listed Observational

Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease

NCT02492672
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
American Regent, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Palo Alto, California • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Preventing Urinary Tract Infection Post-Surgery

NCT01346774
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cranberry powder capsules, Placebo powder capsules
Drug
Lead sponsor
Betsy Foxman
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

NCT06927024
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Active taVNS, Sham taVNS
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 28, 2026, 11:09 PM EDT
Completed No phase listed Observational

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

NCT01598597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Hyperglycemia in Renal Transplantation

NCT01643382
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
Insulin, Insulin, Asp(B28)-
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 28, 2026, 11:09 PM EDT
Withdrawn No phase listed Observational

Presep and Vascath Interaction Study

NCT00739089
View directory record Official record
Conditions
Hemodynamics, Renal Dialysis, Sepsis, Shock
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Not applicable Interventional

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

NCT06525623
View directory record Official record
Conditions
Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT04071223
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
47
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05027074
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
77
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed No phase listed Observational

Registry of Patients Treated by Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures

NCT05141123
View directory record Official record
Conditions
Renal Aneurysm, Aneurysm Thoracic, Aneurysm Abdominal
Interventions
Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for
Procedure
Lead sponsor
IRCCS San Raffaele
Other
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 28, 2026, 11:09 PM EDT
Completed No phase listed Observational Results available

DBS for Home Monitoring in Children With Kidney Transplantation

NCT01931397
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 28, 2026, 11:09 PM EDT
Withdrawn No phase listed Observational

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

NCT04560582
View directory record Official record
Conditions
Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure
Interventions
Blood Draw
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

NCT00971620
View directory record Official record
Conditions
Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid

NCT00007020
View directory record Official record
Conditions
Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis
Interventions
Cholic Acids
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

NCT00624559
View directory record Official record
Conditions
Hypertension
Interventions
celecoxib (Celebrex), Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
22 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study With SNF472 in Calciphylaxis Patients

NCT02790073
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
SNF472
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

NCT05987241
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
495
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

NCT02248051
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Anaheim, California • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 28, 2026, 11:09 PM EDT
Recruiting No phase listed Observational

Healthy Living BEYOND Weight Study

NCT07075341
View directory record Official record
Conditions
Overweight or Obesity
Interventions
None - Observational study
Other
Lead sponsor
American Heart Association
Other
Eligibility
18 Years and older
Enrollment
1,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2060
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Not yet recruiting Phase 4 Interventional

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

NCT07155694
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone 10 MG, Empagliflozin 10 MG
Drug
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
20 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

NCT02060370
View directory record Official record
Conditions
Genitourinary Cancer, Kidney Cancer
Interventions
Sunitinib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
5
States / cities
Stanford, California • Chapel Hill, North Carolina • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease

NCT03223883
View directory record Official record
Conditions
Chronic Kidney Diseases, Cognitive Decline
Interventions
Curcumin, Placebo
Drug · Other
Lead sponsor
Diana Jalal
Other
Eligibility
45 Years to 74 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 28, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury

NCT03236441
View directory record Official record
Conditions
Contrast-induced Acute Kidney Injury
Interventions
RIPC, Sham-RIPC
Device
Lead sponsor
Oladipupo Olafiranye, MD, MS
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 28, 2026, 11:09 PM EDT